VivekSubbiahMD

Oncology • Nashville, TN

Endocrine Cancer, Hematologic Oncology, Sarcoma

Chief, Early-Phase Drug Development, SCRI

Join to view full profile

Dr. Subbiah is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Subbiah's full profile

Already have an account?

Office
335 24th Ave N #200
Nashville, TN 37203
Phone+1 615-329-7640
Is this information wrong?

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2011 - 2012
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Pediatric Hematology/Oncology, 2008 - 2011
The MetroHealth System/Case Western Reserve UniversityResidency, Internal Medicine/Pediatrics, 2004 - 2008
Sri Ramachandra Medical CollegeClass of 2002

Certifications & Licensure

FL State Medical License 2021 - Present
TX State Medical License 2010 - 2025
TN State Medical License 2023 - 2024
OK State Medical License 2020 - 2021
OH State Medical License 2004 - 2009
American Board of Internal Medicine Medical Oncology

Clinical Trials

Trial of Curcumin in Advanced Pancreatic Cancer Start of enrollment: 2004 Nov 01
Completed
Phase 2
Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer Start of enrollment: 2012 May 14
Active, not recruiting
Phase 1
Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer Start of enrollment: 2012 Dec 18
Completed
Phase 1
Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma Start of enrollment: 2013 Oct 16
Completed
Phase 1, Phase 2
Safety and Efficacy Study of DCVax-Direct in Solid Tumors Start of enrollment: 2013 Jun 01
Unknown status
Phase 1, Phase 2
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors Start of enrollment: 2013 Oct 01
Completed
Phase 1
A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma Start of enrollment: 2013 Nov 01
Regorafenib and Cetuximab in Patients With Advanced Malignancy Start of enrollment: 2014 Mar 19
Completed
Phase 1
Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) Start of enrollment: 2014 Sep 17
Terminated
Phase 2
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) Start of enrollment: 2014 Aug 25
Completed
Phase 2
Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers Start of enrollment: 2018 Mar 12
Completed
Phase 1
Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors Start of enrollment: 2018 Mar 12
Completed
Phase 1
A Study of LY3405105 in Participants With Advanced Cancer Start of enrollment: 2019 Jan 31
Terminated
Phase 1
Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study Start of enrollment: 2019 Dec 14
Active, not recruiting
Phase 2
The Registry of Oncology Outcomes Associated With Testing and Treatment Start of enrollment: 2021 May 05
Recruiting
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors Start of enrollment: 2020 Aug 01
Recruiting
Phase 1, Phase 2
TCF-001 TRACK (Target Rare Cancer Knowledge) Study Start of enrollment: 2020 Oct 01
Recruiting
Not Applicable
Join now to see all

Publications & Presentations

PubMed

A Vision for Democratizing Next-Generation Oncology Clinical Trials.
Denis Horgan, Vivek Subbiah, Ishwaria M Subbiah> ;Cancer Discovery. 2024 Apr 4
Tissue-Agnostic Cancer Therapy Approvals.
Gouda, M., Subbiah, V.> ;Surgical Oncology Clinics of North America. 2024 Apr 1
RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study.
Jason Roszik, Carmelia Maria Noia Barretto, Erick Campbell, Amber M Johnson, Isabella C Glitza Oliva, Blessie Elizabeth Nelson, Jibran Ahmed, Mirella Nardo, Sarina A P...> ;Molecular Cancer. 2024 Mar 26
The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer.
Mary K Nesline, Vivek Subbiah, Rebecca A Previs, Kyle C Strickland, Heidi Ko, Paul DePietro, Michael D Biorn, Maureen Cooper, Nini Wu, Jeffrey Conroy, Sarabjot Pabla, ...> ;Oncology and Therapy. 2024 Mar 19
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer.
Gouda, M., Iorgulescu, J., Shen, T., Wu, J., Subbiah, V., Dadu, R., Patel, K., Sherman, S., Cabanillas, M., Hu, M., Castellanos, L., Amini, B., Meric-Bernstam, F.> ;NPJ Precision Oncology. 2024 Mar 4
Modernize Precision Oncology With Decentralized Trial Tools.
Muhammad Shaalan Beg, Vivek Subbiah> ;JAMA Oncology. 2024 Apr 1
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid M...
Subbiah, V., Coleman, N., Piha-Paul, S., Tsimberidou, A., Janku, F., Rodon, J., Pant, S., Dumbrava, E., Fu, S., Hong, D., Zhang, S., Sun, M., Jiang, Y., Roszik, J., So...> ;Cancer Research Communications. 2024 Feb 12
Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW study.
Lin, J. J., Frank Griesinger, Giuseppe Curigliano, Vivek Subbiah, Christina S Baik, Daniel Sw Tan, Dae H Lee, Daniel Misch, Elena Garralda, Dong-Wan Kim, Anthonie J va...> ;Future Oncology. 2024 Feb 1
Targeting AllAlterations: The (Re)-Search Continues.
Pellatt, A., Bhamidipati, D., Subbiah, V.> ;JCO Precision Oncology. 2024 Feb 1
Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases.
Solange Peters, José Trigo, Benjamin Besse, Victor Moreno, Alejandro Navarro, Maria Eugenia Olmedo, Luis Paz-Ares, Christian Grohé, José Antonio Lopez-Vilariño, Cristi...> ;Lung Cancer. 2024 Feb 1
Predicting the Abscopal Phenomenon-Reply.
Nelson, B., Subbiah, V.> ;Molecular Cancer Therapeutics. 2024 Feb 1
Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors.
Coleman, N., Stephen, B., Ahnert, J., Wright, J., Fessahaye, S., Ouyang, F., Yilmaz, B., Fu, S., Karp, D., Subbiah, V., Piha-Paul, S., Meric-Bernstam, F., Naing, A.> ;Cancer Medicine. 2024 Feb 1
Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers.
Kristian Thorlund, Stephen Duffield, Sanjay Popat, Sreeram Ramagopalan, Alind Gupta, Grace Hsu, Paul Arora, Vivek Subbiah> ;Journal of Comparative Effectiveness Research. 2024 Mar 1
1 citations
Interpreting and integrating genomic tests results in clinical cancer care: Overview and practical guidance.
Raffaella Casolino, Philip A Beer, Debyani Chakravarty, Melissa B Davis, Umberto Malapelle, Luca Mazzarella, Nicola Normanno, Chantal Pauli, Vivek Subbiah, Clare Turnb...> ;CA. 2024 Jan 4
Impact of tissue-agnostic approvals on management of primary brain tumors.
Ahluwalia, M., Ozair, A., Gouda, M., Khosla, A., Subbiah, V.> ;Trends in Cancer. 2024 Mar 1
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
Vivek Subbiah, Mimi I Hu, Aaron S Mansfield, Matthew H Taylor, Martin Schuler, Viola W Zhu, Julien Hadoux, Giuseppe Curigliano, Lori Wirth, Justin F Gainor, Guzman Alo...> ;Thyroid. 2024 Jan 1
1 citations
Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers.
Gouda, M., Barreto, C., Slade, J., Poullard, A., Zafereo, M., Nardo, M., Nelson, B., Hu, M., Cabanillas, M., Subbiah, V.> ;Cell Reports. Medicine. 2023 Dec 19
1 citations
Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types.
Pashtoon M Kasi, Jessica K Lee, Lincoln W Pasquina, Brennan Decker, Pierre Vanden Borre, Dean C Pavlick, Justin M Allen, Christine Parachoniak, Julia C F Quintanilha, ...> ;Clinical Cancer Research. 2024 Feb 16
Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes.
Conley, A. P., Denu, R., Yang, R., Lazar, A., Patel, S., Lewis, V., Roszik, J., Livingston, J., Wang, W., Shaw, K., Ratan, R., Zarzour, M., Bird, J., Raza, S., Akdemir...> ;Clinical Cancer Research. 2023 Dec 1
1 citations
Revolutionizing cancer drug development: Harnessing the potential of basket trials.
Vivek Subbiah, Howard A Burris 3rd, Razelle Kurzrock> ;Cancer. 2024 Jan 1
Association between treatment and improvements in overall survival of patients with advanced/metastatic non-small cell lung cancer since 2011: A study in the United St...
Frank Griesinger, Sreeram Ramagopalan, Winson Y Cheung, Thomas Wilke, Sabrina Mueller, Alind Gupta, Dylan E O'Sullivan, Paul Arora, Darren R Brenner, Carolin Froelich,...> ;Cancer. 2024 Feb 15
Transporting Comparative Effectiveness Evidence Between Countries: Considerations for Health Technology Assessments.
Alex J Turner, Cormac Sammon, Nick Latimer, Blythe Adamson, Brennan Beal, Vivek Subbiah, Keith R Abrams, Joshua Ray> ;Pharmacoeconomics. 2024 Feb 1
RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond.
Jie Wu, Vivek Subbiah> ;Cancer Research. 2023 Oct 2
TRKing sarcomas for precision medicine: Seek, and ye shall find!
Justin T Moyers, Vivek Subbiah> ;Cancer. 2023 Dec 1
4 citations
Clinical development and management of adverse events associated with FGFR inhibitors.
Vivek Subbiah, Srdan Verstovsek> ;Cell Reports. Medicine. 2023 Oct 17
Join now to see all

Lectures

Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Efficacy and safety of lurbinectedin (PM1183) in Ewing sarcoma: Final results from a phase 2 study.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Vivek Subbiah, MD, Joins SCRI to Advance Early-Phase Clinical ResearchMay 11th, 2023
His Thyroid Cancer Was Too Rare for Doctors to Treat. After a Trial, Woodlands Man Now Cancer-FreeDecember 14th, 2022
Single-Arm Phase 1/2 Study | Tumor-Agnostic Efficacy and Safety of Selpercatinib in Patients with RET Fusion-Positive Solid Tumors Other Than Lung or Thyroid TumorsSeptember 20th, 2022
Join now to see all